RxDoctor Payments Data

Maurice Vincent, MD

Family Medicine · Brea, CANPI 1588611990

Payments from drug & device makers

$3,988in general payments, 2019–2025

Across 208 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$837
  • Pfizer$645
  • AbbVie$371
  • Astellas Pharma US Inc$316
  • AstraZeneca$297
  • Abbott$285
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,60790%
  • Education$38110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,988 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$24,049
Medicare patients
72
Services billed
215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide119$145,010
EliquisApixaban96$92,520
HumiraAdalimumab12$81,968
TrulicityDulaglutide36$51,479
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$38,147
JanuviaSitagliptin Phosphate33$33,740
JanumetSitagliptin Phos/Metformin Hcl14$15,547
MounjaroTirzepatide13$14,835
JardianceEmpagliflozin16$12,035
PremarinEstrogens, Conjugated20$10,926
MyrbetriqMirabegron15$10,640
Spiriva RespimatTiotropium Bromide12$6,995
Levothyroxine Sodium426$6,380
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$5,586
Humalog Kwikpen U-100Insulin Lispro12$4,993

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$141$145,010119 claims
PfizerEliquis, Premarin, Paxlovid$645$106,181128 claims
AbbVieHumira, Synthroid$371$84,64151 claims
Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30, Olanzapine$233$71,30390 claims
GSKTrelegy Ellipta$837$38,14757 claims
Boehringer IngelheimJardiance, Spiriva Respimat$253$19,03028 claims
Astellas Pharma US IncMyrbetriq$316$10,64015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Brea

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →